Filter Results
Clinical Studies
Results filtered:Study status:
Open
Closed for Enrollment
Open
-
A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients with Relapsed and Refractory Multiple Myeloma
Rochester, Minn.,
Jacksonville, Fla.,
Scottsdale/Phoenix, Ariz.
The purpose of this study is to determine the maximum tolerated dose (MTD) and schedule and/or a recommended Phase 2 dose (RP2D) and schedule of KTX-1001 for patients with relapsed and refractory multiple myeloma.
-
Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
Rochester, Minn.,
Scottsdale/Phoenix, Ariz.,
Jacksonville, Fla.
The primary purpose of this study is to learn more about what makes stem cell transplants work well, such as determining the following:
- How well recipients recover from their transplant;
- How recovery after a transplant can be improved;
- How access to transplant for different groups of patients can be improved;
- How well donors recover from the collection procedures.
Closed for Enrollment
-
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-‑Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab (STORM)
Rochester, Minn.,
Scottsdale/Phoenix, Ariz.
This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus dexamethasone 20 mg (Sd) dosed twice weekly in four-week cycles, in patients with penta-refractory MM (Parts 1 and 2) or quad refractory MM (Part 1 only).
-
H125001 - An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed or Refractory Multiple Myeloma (EVOLVE)
Rochester, Minn.
The purpose of this study is to determine the safety and effectiveness of JCARH125 in adult subjects with relapsed and/or refractory multiple myeloma. The study will include a Phase 1 part to determine the recommended dose of JCARH125 in subjects with relapsed and/or refractory multiple myeloma, followed by a Phase 2 part to further evaluate the safety and efficacy of JCARH125 at the recommended dose.
-
Observational Registry study of Patients with Paroxysmal Nocturnal Hemoglobinuria treated with Pegcetacoplan
Rochester, Minn.
The purpose of this study is to establish a registry to characterize the long-term safety of pegcetacoplan in adult patients with PNH, including patients who are treatment naïve, with at
least 5 years of follow-up.
-
Somatic Mutations and Pathobiology of Schnitzler Syndrome
Rochester, Minn.
This study will perform whole exome sequencing on patients with Schnitzler syndrome to determine whether subclonal mutation are present.
.